At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 49 enrolled
Drug / intervention
Ublituximab +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Placebo-Controlled Multi-Center Phase IIa Dose Finding Study of Ublituximab, a Third-Generation Anti-CD20 Monoclonal Antibody, in Patients With Relapsing Forms of Multiple Sclerosis.
In Brief
A Phase 2 clinical trial evaluating Ublituximab and Placebo for Multiple Sclerosis. Completed, enrolled 49 participants across 12 sites.
Detailed Summary
This study evaluates the use of single agent ublituximab, a novel monoclonal antibody, in participants with relapsing forms of multiple sclerosis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Sclerosis
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedApr 2016
Enrollment StartMay 2016
Primary CompletionSep 2017
Study CompletionAug 2018
TodayJul 2026
First PostedApr 14, 2016
Enrollment StartMay 27, 2016
Primary CompletionSep 27, 2017
Study CompletionAug 13, 2018
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 10.2 years ago
Interventions
Ublituximabbiological
Administered as an IV infusion.
Placebodrug